FDA commissioner watch intensifies as FDA reform bill nears completion.
This article was originally published in The Gray Sheet
Executive Summary
FDA COMMISSIONER WATCH INTENSIFIES: COMPLETION OF FDA REFORM BILL is a logical time for a White House nomination to be forwarded to the Senate. Delay would suggest that the nomination of HHS' preferred candidate, FDA Lead Deputy Commissioner Michael Friedman, MD, has run into turbulence.